BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 16381002)

  • 1. Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response.
    Kronblad A; Jirström K; Rydén L; Nordenskjöld B; Landberg G
    Int J Cancer; 2006 May; 118(10):2609-16. PubMed ID: 16381002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
    Brennan DJ; Jirstrom K; Kronblad A; Millikan RC; Landberg G; Duffy MJ; Rydén L; Gallagher WM; O'Brien SL
    Clin Cancer Res; 2006 Nov; 12(21):6421-31. PubMed ID: 17085655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.
    Generali D; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield S; Bersiga A; Allevi G; Milani M; Aguggini S; Gandolfi V; Dogliotti L; Bottini A; Harris AL; Fox SB
    Clin Cancer Res; 2006 Aug; 12(15):4562-8. PubMed ID: 16899602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
    Gruber G; Greiner RH; Hlushchuk R; Aebersold DM; Altermatt HJ; Berclaz G; Djonov V
    Breast Cancer Res; 2004; 6(3):R191-8. PubMed ID: 15084243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
    Berglund P; Stighall M; Jirström K; Rydén L; Fernö M; Nordenskjöld B; Landberg G
    J Clin Pathol; 2008 Feb; 61(2):184-91. PubMed ID: 17483245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients.
    Stendahl M; Nilsson S; Wigerup C; Jirström K; Jönsson PE; Stål O; Landberg G
    Int J Cancer; 2010 Dec; 127(12):2851-8. PubMed ID: 21351264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer.
    Jögi A; Ehinger A; Hartman L; Alkner S
    PLoS One; 2019; 14(12):e0226150. PubMed ID: 31821370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Hypoxia-Inducible Factor 1α in Invasive Breast Cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and EPO-R.
    Badowska-Kozakiewicz A; Sobol M; Patera J
    Adv Clin Exp Med; 2016; 25(4):741-50. PubMed ID: 27629849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer.
    Yamamoto Y; Ibusuki M; Okumura Y; Kawasoe T; Kai K; Iyama K; Iwase H
    Breast Cancer Res Treat; 2008 Aug; 110(3):465-75. PubMed ID: 17805961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.
    Jirström K; Rydén L; Anagnostaki L; Nordenskjöld B; Stål O; Thorstenson S; Chebil G; Jönsson PE; Fernö M; Landberg G
    J Clin Pathol; 2005 Nov; 58(11):1135-42. PubMed ID: 16254100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
    J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 17ss-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer.
    Källström AC; Salme R; Rydén L; Nordenskjöld B; Jönsson PE; Stål O
    Eur J Cancer; 2010 Mar; 46(5):892-900. PubMed ID: 20060711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
    Trastour C; Benizri E; Ettore F; Ramaioli A; Chamorey E; Pouysségur J; Berra E
    Int J Cancer; 2007 Apr; 120(7):1451-8. PubMed ID: 17245699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients.
    Dales JP; Garcia S; Meunier-Carpentier S; Andrac-Meyer L; Haddad O; Lavaut MN; Allasia C; Bonnier P; Charpin C
    Int J Cancer; 2005 Sep; 116(5):734-9. PubMed ID: 15849727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related.
    Bos R; van Diest PJ; van der Groep P; Shvarts A; Greijer AE; van der Wall E
    Breast Cancer Res; 2004; 6(4):R450-9. PubMed ID: 15217513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
    Rydén L; Stendahl M; Jonsson H; Emdin S; Bengtsson NO; Landberg G
    Breast Cancer Res Treat; 2005 Jan; 89(2):135-43. PubMed ID: 15692755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.